Clinical trial
A Cancer Research UK Phase I Trial of IMA950 (A Novel Multi-Peptide Vaccine) Plus GM-CSF in Patients With Newly Diagnosed Glioblastoma
NCT01222221 is registered in ClinicalTrials.gov with Cancer Research UK as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Cancer Research UK Phase I Trial of IMA950 (A Novel Multi-Peptide Vaccine) Plus GM-CSF in Patients With Newly Diagnosed Glioblastoma
- Lead sponsor
- Cancer Research UK
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- July 31, 2010
- Completion date
- February 28, 2015
- Enrollment
- 45 (actual)
- Sites
- 7
Conditions
As the registry lists them; a condition with its own page is linked.
brain and central nervous system tumors